Medpace — Financial Overview, Stock Price, Market Cap

Financial Performance

5Y price score: 263

10Y return: 1,765.9%

DATE RANGE:

US$ Per
Share

Earnings per share
Free cash flow per share
Stock price

By default your notes are visible only to you.

250.0

52-week range

628.9

518.54

Your model inputs


Required return / cost of capital
FCFF terminal growth rate

Your fair value & Margin of safety

To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

Forecast:

Valuation

Free Cash Flow Yield

FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per share

4.6 %

Dividend Yield TTM

Market cap $

$ 14,809

Price / Earnings TTM

P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per share

33.9

Price / Book TTM

PEG TTM

Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rate

1.6

Earnings growth and return

LTM

5YR

10YR

Total return (price & dividends)

70 %

180.3 %

1,765.9 %

Free cash flow per share growth

29.2 %

283 %

1,052.6 %

Earnings per share growth

21 %

297.9 %

5,557.1 %

Founded: 1,992

Employees: 5,900

Business Summary: Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

Financials

all figures in USD Millions except per share data

Periods:

View:

Forecast:

Averages

based on historical growth rates (CAGR) and average margins for last 10 or max, available and up to 10 years.

Analysts

Average Revenue and Net Income forecast estimates from analysts who cover the stock.

Custom

you can edit default forecast based on averages or analysts consensus and use it to calculate fair value based on your assumptions.

ㅤ

Actual

10 year gagr

Estimated

Projected

Fiscal

FISCAL PERIOD END DATES

01Earnings per share

Diluted EPS

02FCF per share

03Dividends per share

Adjusted for splits

04Dividends payout, %

05Revenue

06ㅤ% Change

07Net Income

08ㅤ% Margin

09CFO

10ㅤ% Of revenue

11CAPEX

12ㅤ% Change

13FCFF

Free Cash Flow to the Firm = Cash Flows from Operating Activities (09) – Capital Expenditures (11)

14Total assets

15ㅤ% Change

16Total liabilities

17ㅤ% Of assets

18Shareholders Equity

19Net Debt

20Shares Outstanding

Diluted Weighted-average Shares Outstanding

21ㅤ% Change

22ROA

23ROE

24Interest coverage

25Dividend Yield

26P/E Ratio

27Stock price range

28Market Cap

End of Period Market Cap

29FCF Yield

30Average stock price

31 CEO

Fair Value Reference Estimate

Increase
Decrease
Total


Required return / cost of capital
FCFF terminal growth rate
Free cash flow forecast
Terminal value
ㅤPV breakdown
Enterprise value / PV of FCF
ㅤPlus / (Less): Net Debt
ㅤLess: preferred stock
ㅤLess: minority interest
Market cap
ㅤNumber of shares
Price per share

Latest Earnings Call Takeaways

Could not load earnings call summaries.